<![CDATA[Genmab — Juli 2013]]>http://www.nasdaqomxnordic.com/digitalAssets/86/86453_nomxc_turnover26.pdf pæn 13. p
lads til C20

]]>https://dev.proinvestor.com/forum/topic/451460/genmab-juli-2013RSS for NodeFri, 19 Jun 2026 00:15:08 GMTWed, 03 Jul 2013 15:24:44 GMT60<![CDATA[Reply to Genmab — Juli 2013 on Wed, 31 Jul 2013 09:15:24 GMT]]>Hvis ikke interessen kommer tilbage, så kan vi vinke farvel til C20 ret snart

]]>https://dev.proinvestor.com/forum/post/10072440https://dev.proinvestor.com/forum/post/10072440Wed, 31 Jul 2013 09:15:24 GMT<![CDATA[Reply to Genmab — Juli 2013 on Wed, 31 Jul 2013 09:15:01 GMT]]>Uha - det er ikke megen støtte eller volumen, vi har tilbage efter sommerens sell-off

]]>https://dev.proinvestor.com/forum/post/10072435https://dev.proinvestor.com/forum/post/10072435Wed, 31 Jul 2013 09:15:01 GMT<![CDATA[Reply to Genmab — Juli 2013 on Wed, 31 Jul 2013 06:41:42 GMT]]>Strålende gentogen - den havde jeg ikke set før. Tusind tak. bookmark!

]]>https://dev.proinvestor.com/forum/post/10072438https://dev.proinvestor.com/forum/post/10072438Wed, 31 Jul 2013 06:41:42 GMT<![CDATA[Reply to Genmab — Juli 2013 on Wed, 31 Jul 2013 06:28:58 GMT]]>Her: http://ir.genmab.com/downloads.cfm

]]>https://dev.proinvestor.com/forum/post/10072433https://dev.proinvestor.com/forum/post/10072433Wed, 31 Jul 2013 06:28:58 GMT<![CDATA[Reply to Genmab — Juli 2013 on Wed, 31 Jul 2013 06:27:54 GMT]]>Ja. Det er taget fra Genmabs hjemmeside. Hvor fase IV også kan findes nu. Det ligger lidt halvgemt på siden, men findes under investors downloads.

]]>https://dev.proinvestor.com/forum/post/10072439https://dev.proinvestor.com/forum/post/10072439Wed, 31 Jul 2013 06:27:54 GMT<![CDATA[Reply to Genmab — Juli 2013 on Tue, 30 Jul 2013 14:01:31 GMT]]>Har vi set disse resultater med den her detaljereingsgrad tidligere? Thenote postede dem på den anden kanal: http://files.shareholder.com/downloads/AMDA-KPIBN/2404168726x0x671053/739F7EB2-25B7-4C78-8DE8-FD47AB6CEE82/2013_EHA_Dara_150613.pdf

]]>https://dev.proinvestor.com/forum/post/10072430https://dev.proinvestor.com/forum/post/10072430Tue, 30 Jul 2013 14:01:31 GMT<![CDATA[Reply to Genmab — Juli 2013 on Tue, 30 Jul 2013 12:56:45 GMT]]>
Just a moment...

favicon

(jco.ascopubs.org)

]]>https://dev.proinvestor.com/forum/post/10072431https://dev.proinvestor.com/forum/post/10072431Tue, 30 Jul 2013 12:56:45 GMT<![CDATA[Reply to Genmab — Juli 2013 on Tue, 30 Jul 2013 12:56:37 GMT]]>Ofatumumab:

]]>https://dev.proinvestor.com/forum/post/10072437https://dev.proinvestor.com/forum/post/10072437Tue, 30 Jul 2013 12:56:37 GMT<![CDATA[Reply to Genmab — Juli 2013 on Tue, 30 Jul 2013 12:53:14 GMT]]>Ofatumumab: http://bloodjournal.hematologylibrary.org/content/122/4/469.full

]]>https://dev.proinvestor.com/forum/post/10072428https://dev.proinvestor.com/forum/post/10072428Tue, 30 Jul 2013 12:53:14 GMT<![CDATA[Reply to Genmab — Juli 2013 on Tue, 30 Jul 2013 12:48:53 GMT]]>er det ikke den første generiske?

]]>https://dev.proinvestor.com/forum/post/10072429https://dev.proinvestor.com/forum/post/10072429Tue, 30 Jul 2013 12:48:53 GMT<![CDATA[Reply to Genmab — Juli 2013 on Tue, 30 Jul 2013 12:39:12 GMT]]>in the state of the art, Asia's only EU GMP facility of Intas Biopharmaceuticals, Ahmedabad.

]]>https://dev.proinvestor.com/forum/post/10072432https://dev.proinvestor.com/forum/post/10072432Tue, 30 Jul 2013 12:39:12 GMT<![CDATA[Reply to Genmab — Juli 2013 on Tue, 30 Jul 2013 12:38:41 GMT]]>Intas launches Mabtas, a biosimilar version of Rituximab May 02, 2013
Intas Pharmaceuticals Ltd. has launched Mabtas, a biosimilar version of Rituximab competent in
treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B
cells like Chronic Lymphocytic Leukaemia (CLL) and Rheumatoid Arthritis apart from Non-Hodgkin's
Lymphoma (NHL) in India. With a view to make NHL treatment cost-effective, Mabtas is manufactured

]]>https://dev.proinvestor.com/forum/post/10072427https://dev.proinvestor.com/forum/post/10072427Tue, 30 Jul 2013 12:38:41 GMT<![CDATA[Reply to Genmab — Juli 2013 on Tue, 30 Jul 2013 07:22:26 GMT]]>tak for den Gen - du er en ørn til at finde info omkring GEN!

]]>https://dev.proinvestor.com/forum/post/10072436https://dev.proinvestor.com/forum/post/10072436Tue, 30 Jul 2013 07:22:26 GMT<![CDATA[Reply to Genmab — Juli 2013 on Tue, 30 Jul 2013 06:13:37 GMT]]>Også lidt her (dog ikke ny): Se under David Satijn ved at scrolle ned: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502230/

]]>https://dev.proinvestor.com/forum/post/10072434https://dev.proinvestor.com/forum/post/10072434Tue, 30 Jul 2013 06:13:37 GMT<![CDATA[Reply to Genmab — Juli 2013 on Mon, 29 Jul 2013 22:26:40 GMT]]>Martin Schultz: First in Human Protocol for the Compound HuMax-TF-ADC, Master's project, June 2013, Faculty of Health and Medical Sciences, University of Copenhagen.

]]>https://dev.proinvestor.com/forum/post/10072423https://dev.proinvestor.com/forum/post/10072423Mon, 29 Jul 2013 22:26:40 GMT<![CDATA[Reply to Genmab — Juli 2013 on Mon, 29 Jul 2013 17:23:45 GMT]]>http://finance.yahoo.com/q?s=GNMSF 50.000 stk
omsat

]]>https://dev.proinvestor.com/forum/post/10072426https://dev.proinvestor.com/forum/post/10072426Mon, 29 Jul 2013 17:23:45 GMT<![CDATA[Reply to Genmab — Juli 2013 on Mon, 29 Jul 2013 12:24:41 GMT]]>http://bloodjournal.hematologylibrary.org/content/118/19/5126.short

]]>https://dev.proinvestor.com/forum/post/10072424https://dev.proinvestor.com/forum/post/10072424Mon, 29 Jul 2013 12:24:41 GMT<![CDATA[Reply to Genmab — Juli 2013 on Mon, 29 Jul 2013 11:24:02 GMT]]>jep - godkendelsen var baseret på ORR=42% - http://www.hematology.org/News/2009/4384.aspx

]]>https://dev.proinvestor.com/forum/post/10072422https://dev.proinvestor.com/forum/post/10072422Mon, 29 Jul 2013 11:24:02 GMT<![CDATA[Reply to Genmab — Juli 2013 on Mon, 29 Jul 2013 11:22:27 GMT]]>Mener den var i 40´erne før, men er ikke sikker - fik som sagt aldrig helt checket op på det

]]>https://dev.proinvestor.com/forum/post/10072425https://dev.proinvestor.com/forum/post/10072425Mon, 29 Jul 2013 11:22:27 GMT<![CDATA[Reply to Genmab — Juli 2013 on Mon, 29 Jul 2013 11:18:21 GMT]]>orr er 23%

]]>https://dev.proinvestor.com/forum/post/10072421https://dev.proinvestor.com/forum/post/10072421Mon, 29 Jul 2013 11:18:21 GMT<![CDATA[Reply to Genmab — Juli 2013 on Mon, 29 Jul 2013 11:18:11 GMT]]>står på side 47 i denne rapport: http://www.haematologica.org/content/98/supplement_1/1.full.pdf

]]>https://dev.proinvestor.com/forum/post/10072417https://dev.proinvestor.com/forum/post/10072417Mon, 29 Jul 2013 11:18:11 GMT<![CDATA[Reply to Genmab — Juli 2013 on Mon, 29 Jul 2013 11:17:39 GMT]]>Du har ret sukker - Summary / Conclusion:These results show that with the only exception of the ORR
(lower in this study) all endpoints (PFS, OS) and safety profile in CLL patients treated with ofatumumab in daily practice are consistent with those observed in phase II
and III clinical trials.

]]>https://dev.proinvestor.com/forum/post/10072415https://dev.proinvestor.com/forum/post/10072415Mon, 29 Jul 2013 11:17:39 GMT<![CDATA[Reply to Genmab — Juli 2013 on Mon, 29 Jul 2013 11:10:31 GMT]]>Det var ORR der var dårligere - en del dårligere så vidt jeg husker ! Ville egentlig have skrevet til Rachel for en kommentar, men det glemte jeg.

]]>https://dev.proinvestor.com/forum/post/10072419https://dev.proinvestor.com/forum/post/10072419Mon, 29 Jul 2013 11:10:31 GMT<![CDATA[Reply to Genmab — Juli 2013 on Mon, 29 Jul 2013 11:04:42 GMT]]>jeg mener bestemt, at det var pfs. Det stod vistnok på side 54, men nu kan jeg ikke genfinde rapporten

]]>https://dev.proinvestor.com/forum/post/10072416https://dev.proinvestor.com/forum/post/10072416Mon, 29 Jul 2013 11:04:42 GMT